- Home
- DDD vs ZURA Comparison
DDD vs ZURA Comparison
Compare DDD & ZURA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | DDD | ZURA |
|---|---|---|
| Founded | 1986 | 2022 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Computer peripheral equipment | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 285.8M | 252.9M |
| IPO Year | N/A | N/A |
Fundamental Metrics
Financial Performance| Metric | DDD | ZURA |
|---|---|---|
| Price | $1.78 | $4.50 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 2 | 8 |
| Target Price | $4.75 | ★ $11.38 |
| AVG Volume (30 Days) | ★ 3.4M | 434.3K |
| Earning Date | 11-04-2025 | 11-13-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ 0.10 | N/A |
| Revenue | ★ $391,651,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $1.31 | N/A |
| P/E Ratio | $17.00 | ★ N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $1.32 | $0.97 |
| 52 Week High | $5.00 | $4.68 |
Technical Indicators
Market Signals| Indicator | DDD | ZURA |
|---|---|---|
| Relative Strength Index (RSI) | 36.88 | 68.03 |
| Support Level | $1.82 | $4.00 |
| Resistance Level | $1.93 | $4.44 |
| Average True Range (ATR) | 0.12 | 0.25 |
| MACD | 0.01 | 0.05 |
| Stochastic Oscillator | 14.34 | 92.46 |
Price Performance
Historical ComparisonAbout DDD 3D Systems Corporation
3D Systems Corp provides comprehensive 3D printing and digital manufacturing solutions, including 3D printers for plastics and metals, materials, software, and services, including maintenance, advanced manufacturing and applications engineering. The company's segments include Healthcare Solutions and Industrial Solutions. It generates maximum revenue from the Industrial segment. It conducts business through various offices and facilities located throughout the Americas, EMEA, and APAC; generating a vast majority of revenues from the Americas.
About ZURA Zura Bio Limited
Zura Bio Ltd is a clinical-stage, multi-asset immunology company developing novel dual-pathway antibodies for autoimmune and inflammatory diseases. It is developing three assets which have completed Phase I/Ib studies and are Phase II ready. It is developing a portfolio of therapeutic indications for tibulizumab and torudokimab with a goal of demonstrating their efficacy, safety, and dosing convenience in autoimmune and inflammatory diseases.